Oct 28 2025 |
et al., medRxiv, doi:10.64898/2026.03.07.26347857 (results released 10/28/25) | A phase 2a double-blind, placebo-controlled randomized trial of the SARS-CoV-2-specific monoclonal antibody AER002 in people with Long COVID |
| 6% higher long COVID (p=0.25). RCT 36 long COVID outpatients showing no significant clinical benefit with the AER002 monoclonal antibody compared to placebo. | ||